J Raymond1, R Klink2, M Chagnon3, S L Barnwell4, A J Evans5, J Mocco6, B L Hoh6, A S Turk7, R D Turner7, H Desal8, D Fiorella9, S Bracard10, A Weill11, F Guilbert11, D Roy11. 1. From the Department of Radiology (J.R., A.W., F.G., D.R.), Centre Hospitalier de l'Université de Montréal Laboratory of Interventional Neuroradiology (J.R., R.K.), Centre de recherche du Centre Hospitalier de l'Université de Montréal, Notre-Dame Hospital, Montreal, Quebec, Canada jean.raymond@umontreal.ca. 2. Laboratory of Interventional Neuroradiology (J.R., R.K.), Centre de recherche du Centre Hospitalier de l'Université de Montréal, Notre-Dame Hospital, Montreal, Quebec, Canada. 3. Département de mathématiques et de statistique (M.C.), Université de Montréal, Montreal, Quebec, Canada. 4. Department of Neurological Surgery (S.L.B.), Oregon Health & Science University, Portland, Oregon. 5. Department of Radiology and Medical Imaging (A.J.E.), University of Virginia Health System, Charlottesville, Virginia. 6. Department of Neurosurgery (J.M., B.L.H.), University of Florida, Gainesville, Florida. 7. Departments of Radiology and Neurosurgery (A.S.T., R.D.T.), Medical University of South Carolina, Charleston, South Carolina. 8. Service de Neuroradiologie Diagnostique et Interventionnelle (H.D.), Centre Hospitalier Universitaire de Nantes, Nantes, France. 9. Department of Neurological Surgery (D.F.), Stony Brook University Medical Center, Stony Brook, New York. 10. Département de Neuroradiologie Diagnostique et Interventionnelle (S.B.), Centre Hospitalier Universitaire de Nancy, Nancy, France. 11. From the Department of Radiology (J.R., A.W., F.G., D.R.), Centre Hospitalier de l'Université de Montréal.
Abstract
BACKGROUND AND PURPOSE: Some patients with large or recurrent aneurysms may be at increased risk of recurrence postcoiling. The Patients Prone to Recurrence after Endovascular Treatment (PRET) trial was designed to assess whether hydrogel coils were superior to platinum coils in these high-risk patients. This article reports periprocedural safety and operator-assessed angiographic results from the PRET trial. MATERIALS AND METHODS: PRET was a pragmatic, multicenter, randomized controlled trial. Patients had ≥10-mm aneurysms (PRET-1) or a major recurrence after coiling of an aneurysm of any size (PRET-2). Patients were randomly allocated to hydrogel or control arms (any platinum coil) by using concealed allocation with minimization. Assist devices could be used as clinically required. Aneurysms could be unruptured or recently ruptured. Analyses were on an intent-to-treat basis. RESULTS:Four hundred forty-seven patients were recruited (250 PRET-1; 197 PRET-2). Aneurysms were recently ruptured in 29% of PRET-1 and 4% of PRET-2 patients. Aneurysms were ≥10 mm in all PRET-1 and in 50% of PRET-2 patients. They were wide-neck (≥4 mm) in 70% and in the posterior circulation in 24% of patients. Stents were used in 28% of patients (35% in PRET-2). Coiling was successful in 98%. Adverse events occurred in 28 patients with hydrogel and 23 with platinum coils. Mortality (n=2, unrelated to treatment) and morbidity (defined as mRS>2 at 1 month) occurred in 25 patients (5.6%; 12 hydrogel, 13 platinum), related to treatment in 10 (4 hydrogel; 6 platinum) (or 2.3% of 444 treated patients). No difference was seen between hydrogel and platinum for any of the indices used to assess safety up to at least 30 days after treatment. At 1 month, 95% of patients were home with a good outcome (mRS≤2 or unchanged). Operator-assessed angiographic outcomes were satisfactory (complete occlusion or residual neck) in 339 of 447 or 76.4% of patients, with no significant difference between groups. CONCLUSIONS: Endovascular treatment of large and recurrent aneurysms can be performed safely with platinum or hydrogel coils.
RCT Entities:
BACKGROUND AND PURPOSE: Some patients with large or recurrent aneurysms may be at increased risk of recurrence postcoiling. The Patients Prone to Recurrence after Endovascular Treatment (PRET) trial was designed to assess whether hydrogel coils were superior to platinum coils in these high-risk patients. This article reports periprocedural safety and operator-assessed angiographic results from the PRET trial. MATERIALS AND METHODS: PRET was a pragmatic, multicenter, randomized controlled trial. Patients had ≥10-mm aneurysms (PRET-1) or a major recurrence after coiling of an aneurysm of any size (PRET-2). Patients were randomly allocated to hydrogel or control arms (any platinum coil) by using concealed allocation with minimization. Assist devices could be used as clinically required. Aneurysms could be unruptured or recently ruptured. Analyses were on an intent-to-treat basis. RESULTS: Four hundred forty-seven patients were recruited (250 PRET-1; 197 PRET-2). Aneurysms were recently ruptured in 29% of PRET-1 and 4% of PRET-2 patients. Aneurysms were ≥10 mm in all PRET-1 and in 50% of PRET-2 patients. They were wide-neck (≥4 mm) in 70% and in the posterior circulation in 24% of patients. Stents were used in 28% of patients (35% in PRET-2). Coiling was successful in 98%. Adverse events occurred in 28 patients with hydrogel and 23 with platinum coils. Mortality (n=2, unrelated to treatment) and morbidity (defined as mRS>2 at 1 month) occurred in 25 patients (5.6%; 12 hydrogel, 13 platinum), related to treatment in 10 (4 hydrogel; 6 platinum) (or 2.3% of 444 treated patients). No difference was seen between hydrogel and platinum for any of the indices used to assess safety up to at least 30 days after treatment. At 1 month, 95% of patients were home with a good outcome (mRS≤2 or unchanged). Operator-assessed angiographic outcomes were satisfactory (complete occlusion or residual neck) in 339 of 447 or 76.4% of patients, with no significant difference between groups. CONCLUSIONS: Endovascular treatment of large and recurrent aneurysms can be performed safely with platinum or hydrogel coils.
Authors: Andrew Molyneux; Richard Kerr; Irene Stratton; Peter Sandercock; Mike Clarke; Julia Shrimpton; Rury Holman Journal: Lancet Date: 2002-10-26 Impact factor: 79.321
Authors: C G McDougall; S Claiborne Johnston; A Gholkar; S L Barnwell; J C Vazquez Suarez; J Massó Romero; J C Chaloupka; A Bonafe; A K Wakhloo; D Tampieri; C F Dowd; A J Fox; S J Imm; K Carroll; A S Turk Journal: AJNR Am J Neuroradiol Date: 2014-01-30 Impact factor: 3.825
Authors: Jean Raymond; François Guilbert; Alain Weill; Stavros A Georganos; Louis Juravsky; Anick Lambert; Julie Lamoureux; Miguel Chagnon; Daniel Roy Journal: Stroke Date: 2003-05-29 Impact factor: 7.914
Authors: Andrew J Molyneux; Alison Clarke; Mary Sneade; Ziyah Mehta; Stuart Coley; Daniel Roy; David F Kallmes; Allan J Fox Journal: Stroke Date: 2012-07-26 Impact factor: 7.914
Authors: Andrew J Molyneux; Richard S C Kerr; Ly-Mee Yu; Mike Clarke; Mary Sneade; Julia A Yarnold; Peter Sandercock Journal: Lancet Date: 2005 Sep 3-9 Impact factor: 79.321
Authors: Adriana Campi; Najib Ramzi; Andrew J Molyneux; Paul E Summers; Richard S C Kerr; Mary Sneade; Julia A Yarnold; Joan Rischmiller; James V Byrne Journal: Stroke Date: 2007-03-29 Impact factor: 7.914
Authors: J Raymond; R Klink; M Chagnon; S L Barnwell; A J Evans; J Mocco; B H Hoh; A S Turk; R D Turner; H Desal; D Fiorella; S Bracard; A Weill; F Guilbert; S Lanthier; A J Fox; T E Darsaut; P M White; D Roy Journal: AJNR Am J Neuroradiol Date: 2017-01-12 Impact factor: 3.825
Authors: Jimmy Ghostine; Naim Khoury; Francis Cloutier; Marc Kotowski; Jean-Christophe Gentric; André L Batista; Alain Weill; Daniel Roy; Tim E Darsaut; Jean Raymond Journal: Interv Neuroradiol Date: 2016-08-16 Impact factor: 1.610
Authors: Francis Cloutier; Naim Khoury; Jimmy Ghostine; Behzad Farzin; Marc Kotowski; Alain Weill; Daniel Roy; Jean Raymond Journal: Interv Neuroradiol Date: 2016-10-22 Impact factor: 1.610
Authors: T Ohta; I Nakahara; R Ishibashi; S Matsumoto; M Gomi; H Miyata; H Nishi; S Watanabe; I Nagata Journal: AJNR Am J Neuroradiol Date: 2014-12-26 Impact factor: 3.825
Authors: J Raymond; D Iancu; W Boisseau; J D B Diestro; R Klink; M Chagnon; J Zehr; B Drake; H Lesiuk; A Weill; D Roy; M W Bojanowski; C Chaalala; J L Rempel; C O'Kelly; M M Chow; S Bracard; T E Darsaut Journal: AJNR Am J Neuroradiol Date: 2022-08-04 Impact factor: 4.966